1. Metabolic Enzyme/Protease Apoptosis
  2. NAMPT Apoptosis
  3. CHS-828

CHS-828 (GMX1778) is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC50 less than 25 nM. CHS-828 (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD+ and exhibits a potent anticancer activity.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CHS-828

CHS-828 화학구조

CAS No. : 200484-11-3

사이즈 가격 재고 수량
무료 샘플 (0.1 - 0.2 mg)   지금 신청하기  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
해외재고보유
Solution
10 mM * 1 mL in DMSO 해외재고보유
Solid
5 mg 해외재고보유
10 mg 해외재고보유
25 mg 해외재고보유
50 mg 해외재고보유
100 mg 해외재고보유
200 mg   견적 받기  
500 mg   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 4 publication(s) in Google Scholar

Other Forms of CHS-828:

Top Publications Citing Use of Products
  • Biological Activity

  • 순도&문서

  • References

  • 고객리뷰

제품 설명

CHS-828 (GMX1778) is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC50 less than 25 nM. CHS-828 (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD+ and exhibits a potent anticancer activity[1].

IC50 & Target

IC50: < 25 nM (NAMPT)[1].

Cellular Effect
Cell Line Type Value Description References
A2780 IC50
0.001 3
Compound: 7; GMX1778
Inhibition of NAMPT in human A2780 cells assessed as decrease in cell viability after 72 hrs by SRB assay
Inhibition of NAMPT in human A2780 cells assessed as decrease in cell viability after 72 hrs by SRB assay
[PMID: 27541271]
A2780 IC50
0.001 3
Compound: 7; GMX1778
Inhibition of NAMPT in human A2780 cells assessed as decrease in cell viability after 72 hrs by SRB assay
Inhibition of NAMPT in human A2780 cells assessed as decrease in cell viability after 72 hrs by SRB assay
[PMID: 27541271]
A2780 IC50
0.005 3
Compound: 1, GMX-1778, CHS828
Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay
[PMID: 24405419]
A2780 IC50
0.005 3
Compound: 1, GMX-1778
Antiproliferative activity against human A2780 cells assessed as growth inhibition after 72 hrs by SRB-based microplate reader analysis
Antiproliferative activity against human A2780 cells assessed as growth inhibition after 72 hrs by SRB-based microplate reader analysis
[PMID: 23859118]
A2780 IC50
0.005 3
Compound: 1, GMX-1778
Antiproliferative activity against human A2780 cells assessed as growth inhibition after 72 hrs by SRB-based microplate reader analysis
Antiproliferative activity against human A2780 cells assessed as growth inhibition after 72 hrs by SRB-based microplate reader analysis
[PMID: 23859118]
A2780 IC50
0.005 3
Compound: 2, GMX1778
Cytotoxicity against human A2780 cells after 72 hrs by SRB assay
Cytotoxicity against human A2780 cells after 72 hrs by SRB assay
[PMID: 23617784]
A2780 IC50
0.005 3
Compound: 1, GMX-1778, CHS828
Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay
[PMID: 24405419]
A2780 IC50
0.005 3
Compound: 2, GMX1778
Cytotoxicity against human A2780 cells after 72 hrs by SRB assay
Cytotoxicity against human A2780 cells after 72 hrs by SRB assay
[PMID: 23617784]
A2780 IC50
0.005 3
Compound: 1, GMX-1778, CHS828
Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay
[PMID: 24405419]
A2780 IC50
0.005 3
Compound: 1, GMX-1778
Antiproliferative activity against human A2780 cells assessed as growth inhibition after 72 hrs by SRB-based microplate reader analysis
Antiproliferative activity against human A2780 cells assessed as growth inhibition after 72 hrs by SRB-based microplate reader analysis
[PMID: 23859118]
A2780 IC50
0.001 3
Compound: 7; GMX1778
Inhibition of NAMPT in human A2780 cells assessed as decrease in cell viability after 72 hrs by SRB assay
Inhibition of NAMPT in human A2780 cells assessed as decrease in cell viability after 72 hrs by SRB assay
[PMID: 27541271]
A2780 IC50
0.005 3
Compound: 2, GMX1778
Cytotoxicity against human A2780 cells after 72 hrs by SRB assay
Cytotoxicity against human A2780 cells after 72 hrs by SRB assay
[PMID: 23617784]
A2780 IC50
0.56 1
Compound: 2, CHS828
Cytotoxicity against human A2780 cells assessed as growth inhibition after 72 hrs by WST-1 assay
Cytotoxicity against human A2780 cells assessed as growth inhibition after 72 hrs by WST-1 assay
[PMID: 24164086]
A2780 IC50
0.56 1
Compound: 2, CHS828
Cytotoxicity against human A2780 cells assessed as growth inhibition after 72 hrs by WST-1 assay
Cytotoxicity against human A2780 cells assessed as growth inhibition after 72 hrs by WST-1 assay
[PMID: 24164086]
A2780 IC50
0.56 1
Compound: 2, CHS828
Cytotoxicity against human A2780 cells assessed as growth inhibition after 72 hrs by WST-1 assay
Cytotoxicity against human A2780 cells assessed as growth inhibition after 72 hrs by WST-1 assay
[PMID: 24164086]
B16 IC50
280 1
Compound: 18
In vitro antiproliferative activity against B16 cell lines
In vitro antiproliferative activity against B16 cell lines
10.1016/S0960-894X(97)10152-4
DLD-1 IC50
2315 1
Compound: CHS 828
Cytotoxicity against human DLD1 cells after 24 hrs by SRB assay
Cytotoxicity against human DLD1 cells after 24 hrs by SRB assay
[PMID: 25147148]
MCF7 IC50
1.6 1
Compound: 2, CHS828
Cytotoxicity against human MCF-7 cells assessed as growth inhibition after 72 hrs by WST-1 assay
Cytotoxicity against human MCF-7 cells assessed as growth inhibition after 72 hrs by WST-1 assay
[PMID: 24164086]
NSCLC IC50
2.7 1
Compound: 18
Evaluated in vitro for antiproliferative activity against NYH cell lines derived from small cell lung cancer
Evaluated in vitro for antiproliferative activity against NYH cell lines derived from small cell lung cancer
10.1016/S0960-894X(97)10152-4
DLD-1 IC50
2315 1
Compound: CHS 828
Anticancer activity against human DLD-1 cells assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human DLD-1 cells assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
DLD-1 IC50
2.315 3
Compound: CHS 828
Antiproliferative activity against human DLD-1 cells
Antiproliferative activity against human DLD-1 cells
[PMID: 34655985]
HA22T cell line IC50
2067 1
Compound: CHS 828
Cytotoxicity against human HA22T cells after 24 hrs by SRB assay
Cytotoxicity against human HA22T cells after 24 hrs by SRB assay
[PMID: 25147148]
PC-3 IC50
4.4 1
Compound: 2; GMX1778
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 5 days by Cell-titer Glo reagent based assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 5 days by Cell-titer Glo reagent based assay
[PMID: 28610984]
DLD-1 IC50
2.315 3
Compound: CHS 828
Antiproliferative activity against human DLD-1 cells
Antiproliferative activity against human DLD-1 cells
[PMID: 34655985]
HA22T cell line IC50
2067 1
Compound: CHS 828
Anticancer activity against human HA22T cells assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human HA22T cells assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
DLD-1 IC50
2315 1
Compound: CHS 828
Cytotoxic activity against DLD1 colon cancer cell line
Cytotoxic activity against DLD1 colon cancer cell line
[PMID: 14980658]
DLD-1 IC50
2315 1
Compound: CHS 828
Cytotoxicity against human DLD1 cells after 24 hrs by SRB assay
Cytotoxicity against human DLD1 cells after 24 hrs by SRB assay
[PMID: 25147148]
HepG2 IC50
1245 1
Compound: CHS 828
Cytotoxicity against human HepG2 cells after 24 hrs by SRB assay
Cytotoxicity against human HepG2 cells after 24 hrs by SRB assay
[PMID: 25147148]
HONE1 cell line IC50
15 1
Compound: CHS 828
Anticancer activity against human HONE1 cell line assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human HONE1 cell line assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
DLD-1 IC50
2315 1
Compound: CHS 828
Anticancer activity against human DLD-1 cells assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human DLD-1 cells assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
HepG2 IC50
1245 1
Compound: CHS 828
Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
HONE1 cell line IC50
15 1
Compound: CHS 828
Cytotoxic activity against HONE1 nasopharyngeal carcinoma cell line
Cytotoxic activity against HONE1 nasopharyngeal carcinoma cell line
[PMID: 14980658]
HeLa IC50
0.04 3
Compound: CHS 828
Antiproliferative activity against human HeLa cells
Antiproliferative activity against human HeLa cells
[PMID: 34655985]
HepG2 IC50
18.3 1
Compound: 2, CHS828
Inhibition of NAMPT in human HepG2 cells using [14C]-nicotinamide/PRPP as substrate assessed as formation of [14C]-nicotinamide mononucleotide after 1 hr by liquid scintillation counting analysis
Inhibition of NAMPT in human HepG2 cells using [14C]-nicotinamide/PRPP as substrate assessed as formation of [14C]-nicotinamide mononucleotide after 1 hr by liquid scintillation counting analysis
[PMID: 24164086]
HONE1 cell line IC50
15 1
Compound: CHS 828
Cytotoxicity against human HONE1 cells after 24 hrs by SRB assay
Cytotoxicity against human HONE1 cells after 24 hrs by SRB assay
[PMID: 25147148]
HepG2 IC50
1245 1
Compound: CHS 828
Cytotoxic activity against HepG2 liver cancer cell line
Cytotoxic activity against HepG2 liver cancer cell line
[PMID: 14980658]
HONE1 cell line IC50
15 1
Compound: CHS 828
Cytotoxicity against human HONE1 cells after 24 hrs by SRB assay
Cytotoxicity against human HONE1 cells after 24 hrs by SRB assay
[PMID: 25147148]
HeLa IC50
0.04 3
Compound: CHS 828
Antiproliferative activity against human HeLa cells
Antiproliferative activity against human HeLa cells
[PMID: 34655985]
MCF7 IC50
18 1
Compound: CHS 828
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
HepG2 IC50
1245 1
Compound: CHS 828
Cytotoxicity against human HepG2 cells after 24 hrs by SRB assay
Cytotoxicity against human HepG2 cells after 24 hrs by SRB assay
[PMID: 25147148]
HONE1 cell line IC50
15 1
Compound: CHS 828
Anticancer activity against human HONE1 cell line assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human HONE1 cell line assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
HepG2 IC50
1245 1
Compound: CHS 828
Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
MCF7 IC50
1.6 1
Compound: 2, CHS828
Cytotoxicity against human MCF-7 cells assessed as growth inhibition after 72 hrs by WST-1 assay
Cytotoxicity against human MCF-7 cells assessed as growth inhibition after 72 hrs by WST-1 assay
[PMID: 24164086]
MCF7 IC50
18 1
Compound: CHS 828
Cytotoxic activity against MCF breast cancer cell line
Cytotoxic activity against MCF breast cancer cell line
[PMID: 14980658]
HepG2 IC50
18.3 1
Compound: 2, CHS828
Inhibition of NAMPT in human HepG2 cells using [14C]-nicotinamide/PRPP as substrate assessed as formation of [14C]-nicotinamide mononucleotide after 1 hr by liquid scintillation counting analysis
Inhibition of NAMPT in human HepG2 cells using [14C]-nicotinamide/PRPP as substrate assessed as formation of [14C]-nicotinamide mononucleotide after 1 hr by liquid scintillation counting analysis
[PMID: 24164086]
MCF7 IC50
18 1
Compound: CHS 828
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
HepG2 IC50
18.3 1
Compound: 2, CHS828
Inhibition of NAMPT in human HepG2 cells using [14C]-nicotinamide/PRPP as substrate assessed as formation of [14C]-nicotinamide mononucleotide after 1 hr by liquid scintillation counting analysis
Inhibition of NAMPT in human HepG2 cells using [14C]-nicotinamide/PRPP as substrate assessed as formation of [14C]-nicotinamide mononucleotide after 1 hr by liquid scintillation counting analysis
[PMID: 24164086]
NUGC IC50
25 1
Compound: CHS 828
Cytotoxicity against human NUGC cells after 24 hrs by SRB assay
Cytotoxicity against human NUGC cells after 24 hrs by SRB assay
[PMID: 25147148]
NUGC IC50
25 1
Compound: CHS 828
Anticancer activity against human NUGC cells assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human NUGC cells assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
NUGC IC50
25 1
Compound: CHS 828
Anticancer activity against human NUGC cells assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human NUGC cells assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
NUGC IC50
25 1
Compound: CHS 828
Cytotoxic activity against NUGC gastric cancer cell line
Cytotoxic activity against NUGC gastric cancer cell line
[PMID: 14980658]
NUGC IC50
25 1
Compound: CHS 828
Cytotoxicity against human NUGC cells after 24 hrs by SRB assay
Cytotoxicity against human NUGC cells after 24 hrs by SRB assay
[PMID: 25147148]
PC-3 IC50
4.4 1
Compound: 2; GMX1778
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 5 days by Cell-titer Glo reagent based assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 5 days by Cell-titer Glo reagent based assay
[PMID: 28610984]
MCF7 IC50
0.018 3
Compound: CHS 828
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
[PMID: 34655985]
MCF7 IC50
31 1
Compound: 18
Evaluated in vitro for antiproliferative activity against MCF-7 cell lines model of hormone dependent breast cancer
Evaluated in vitro for antiproliferative activity against MCF-7 cell lines model of hormone dependent breast cancer
10.1016/S0960-894X(97)10152-4
NCI-H460 IC50
50 1
Compound: 18
Evaluated in vitro for antiproliferative activity against NIC-H460 cell lines derived from large cell carcinoma of the lung
Evaluated in vitro for antiproliferative activity against NIC-H460 cell lines derived from large cell carcinoma of the lung
10.1016/S0960-894X(97)10152-4
MCF7 IC50
1.6 1
Compound: 2, CHS828
Cytotoxicity against human MCF-7 cells assessed as growth inhibition after 72 hrs by WST-1 assay
Cytotoxicity against human MCF-7 cells assessed as growth inhibition after 72 hrs by WST-1 assay
[PMID: 24164086]
MCF7 IC50
18 1
Compound: CHS 828
Cytotoxic activity against MCF breast cancer cell line
Cytotoxic activity against MCF breast cancer cell line
[PMID: 14980658]
MCF7 IC50
0.018 3
Compound: CHS 828
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
[PMID: 34655985]
MCF7 IC50
18 1
Compound: CHS 828
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
YOSHIDA IC50
140 1
Compound: 18
In vitro antiproliferative activity against Yoshida cell lines
In vitro antiproliferative activity against Yoshida cell lines
10.1016/S0960-894X(97)10152-4
MCF7 IC50
31 1
Compound: 18
Evaluated in vitro for antiproliferative activity against MCF-7 cell lines model of hormone dependent breast cancer
Evaluated in vitro for antiproliferative activity against MCF-7 cell lines model of hormone dependent breast cancer
10.1016/S0960-894X(97)10152-4
B16 IC50
280 1
Compound: 18
In vitro antiproliferative activity against B16 cell lines
In vitro antiproliferative activity against B16 cell lines
10.1016/S0960-894X(97)10152-4
WALKER IC50
500 1
Compound: 18
In vitro antiproliferative activity against Walker cell line
In vitro antiproliferative activity against Walker cell line
10.1016/S0960-894X(97)10152-4
Lewis lung carcinoma cell line IC50
560 1
Compound: 18
In vitro antiproliferative activity against Lewis cell lines
In vitro antiproliferative activity against Lewis cell lines
10.1016/S0960-894X(97)10152-4
NCI-H460 IC50
50 1
Compound: 18
Evaluated in vitro for antiproliferative activity against NIC-H460 cell lines derived from large cell carcinoma of the lung
Evaluated in vitro for antiproliferative activity against NIC-H460 cell lines derived from large cell carcinoma of the lung
10.1016/S0960-894X(97)10152-4
NSCLC IC50
2.7 1
Compound: 18
Evaluated in vitro for antiproliferative activity against NYH cell lines derived from small cell lung cancer
Evaluated in vitro for antiproliferative activity against NYH cell lines derived from small cell lung cancer
10.1016/S0960-894X(97)10152-4
HepG2 IC50
1245 1
Compound: CHS 828
Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human HepG2 cells assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
NUGC IC50
25 1
Compound: CHS 828
Cytotoxic activity against NUGC gastric cancer cell line
Cytotoxic activity against NUGC gastric cancer cell line
[PMID: 14980658]
HepG2 IC50
1245 1
Compound: CHS 828
Cytotoxic activity against HepG2 liver cancer cell line
Cytotoxic activity against HepG2 liver cancer cell line
[PMID: 14980658]
NUGC IC50
25 1
Compound: CHS 828
Cytotoxicity against human NUGC cells after 24 hrs by SRB assay
Cytotoxicity against human NUGC cells after 24 hrs by SRB assay
[PMID: 25147148]
HepG2 IC50
1245 1
Compound: CHS 828
Cytotoxicity against human HepG2 cells after 24 hrs by SRB assay
Cytotoxicity against human HepG2 cells after 24 hrs by SRB assay
[PMID: 25147148]
NUGC IC50
25 1
Compound: CHS 828
Anticancer activity against human NUGC cells assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human NUGC cells assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
HA22T cell line IC50
2067 1
Compound: CHS 828
Anticancer activity against human HA22T cells assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human HA22T cells assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
PC-3 IC50
4.4 1
Compound: 2; GMX1778
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 5 days by Cell-titer Glo reagent based assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 5 days by Cell-titer Glo reagent based assay
[PMID: 28610984]
HA22T cell line IC50
2067 1
Compound: CHS 828
Cytotoxic activity against HA22T liver cancer cell line
Cytotoxic activity against HA22T liver cancer cell line
[PMID: 14980658]
HA22T cell line IC50
2067 1
Compound: CHS 828
Cytotoxicity against human HA22T cells after 24 hrs by SRB assay
Cytotoxicity against human HA22T cells after 24 hrs by SRB assay
[PMID: 25147148]
WALKER IC50
500 1
Compound: 18
In vitro antiproliferative activity against Walker cell line
In vitro antiproliferative activity against Walker cell line
10.1016/S0960-894X(97)10152-4
YOSHIDA IC50
140 1
Compound: 18
In vitro antiproliferative activity against Yoshida cell lines
In vitro antiproliferative activity against Yoshida cell lines
10.1016/S0960-894X(97)10152-4
DLD-1 IC50
2315 1
Compound: CHS 828
Anticancer activity against human DLD-1 cells assessed as cell growth inhibition incubated for 24 hrs
Anticancer activity against human DLD-1 cells assessed as cell growth inhibition incubated for 24 hrs
[PMID: 35694689]
DLD-1 IC50
2315 1
Compound: CHS 828
Cytotoxic activity against DLD1 colon cancer cell line
Cytotoxic activity against DLD1 colon cancer cell line
[PMID: 14980658]
DLD-1 IC50
2315 1
Compound: CHS 828
Cytotoxicity against human DLD1 cells after 24 hrs by SRB assay
Cytotoxicity against human DLD1 cells after 24 hrs by SRB assay
[PMID: 25147148]
In Vitro

The phosphoribosyltransferase activity of recombinant NAMPT was sensitive to inhibition by CHS-828 (GMX1778) (IC50 < 25 nM) whereas the adenyltransferase activity of recombinant NMNAT1 was not. The Kd of recombinant NAMPT for GMX1778 labeled with a fluorescent tag (CHS-828 (GMX1778)-Alexa Fluor) was 120 nM. Overexpression of wild-type NAMPT was able to maintain a certain level of NAD+ under conditions of challenge with 3 nM GMX1778, but this effect was lost when cells were exposed to 300 nM CHS-828 (GMX1778)[1]. CHS-828 (GMX1778) increases intracellular ROS in cancer cells by elevating the superoxide level while decreasing the intracellular NAD(+) level. Notably, CHS-828 (GMX1778) treatment does not induce ROS in normal cells. CHS-828 (GMX1778)-induced ROS can be diminished by adding nicotinic acid (NA) in a NA phosphoribosyltransferase 1 (NAPRT1)-dependent manner[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

A 4-h iv infusion of NA (120 mg/kg of body weight) did not adversely affect the antitumor activity of a 24-h iv infusion of CHS-828 (GMX1778) at a dose of 150 mg/kg or 650 mg/kg in the NAPRT1-deficient xenograft experiments. CHS-828 (GMX1778) at 650 mg/kg is above the maximum tolerated dose. The administration of NA as a 4-h iv infusion immediately following treatment with 750 mg/kg CHS-828 (GMX1778) reduced the mortality associated with toxic doses of GMX1777[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
분자량

371.86

화학식

C19H22ClN5O

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

N#CN/C(NCCCCCCOC1=CC=C(C=C1)Cl)=N\C2=CC=NC=C2

선적

Room temperature in continental US; may vary elsewhere.

보관
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
용액&용해도
In Vitro: 

DMSO : ≥ 39 mg/mL (104.88 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.6892 mL 13.4459 mL 26.8918 mL
5 mM 0.5378 mL 2.6892 mL 5.3784 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • 몰농도 계산기

  • 농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (6.72 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.6892 mL 13.4459 mL 26.8918 mL 67.2296 mL
5 mM 0.5378 mL 2.6892 mL 5.3784 mL 13.4459 mL
10 mM 0.2689 mL 1.3446 mL 2.6892 mL 6.7230 mL
15 mM 0.1793 mL 0.8964 mL 1.7928 mL 4.4820 mL
20 mM 0.1345 mL 0.6723 mL 1.3446 mL 3.3615 mL
25 mM 0.1076 mL 0.5378 mL 1.0757 mL 2.6892 mL
30 mM 0.0896 mL 0.4482 mL 0.8964 mL 2.2410 mL
40 mM 0.0672 mL 0.3361 mL 0.6723 mL 1.6807 mL
50 mM 0.0538 mL 0.2689 mL 0.5378 mL 1.3446 mL
60 mM 0.0448 mL 0.2241 mL 0.4482 mL 1.1205 mL
80 mM 0.0336 mL 0.1681 mL 0.3361 mL 0.8404 mL
100 mM 0.0269 mL 0.1345 mL 0.2689 mL 0.6723 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

최근 본 상품:

온라인 문의

Your information is safe with us. * Required Fields.

상품명

 

Requested Quantity *

고객명 *

 

호칭

메일주소 *

 

전화번호 *

Department

 

회사명 *

City

Country or Region *

     

비고

대량구매 문의

Inquiry Information

상품명:
CHS-828
Cat. No.:
HY-10079
수량:
MCE Japan Authorized Agent: